September 23, 2021
In Vitro Diagnostics

In Vitro Diagnostics Market Size Valuation To Exceed US$ 85.23 Bn by 2027

Precedence Research has published a new report titled “In Vitro Diagnostics Market (By Product Type: Reagents, Instruments, Services; By Technology: Hematology, Molecular Diagnostics, Immunology, Coagulation, Clinical Chemistry, Microbiology, Others; By Application: Diabetes, Cardiology, Nephrology, Infectious Disease, Oncology, Drug Testing, Autoimmune Diseases, Others; By End Use: Laboratory, Hospital, Home Care, Others) – Global Market Size, Trends Analysis, Segment Forecasts, Regional Outlook 2020 – 2027”, the global In Vitro Diagnostics market size is expected to grow US$ 85.23 Billion by 2027, decelerating at a CAGR of over 5% from 2020 to 2027. The report contains 150+ pages with detailed analysis.

The global In Vitro Diagnostics market research report gives a brief summary of definitions, size analysis and place of production, sales, applications, types, and major players/key vendors of the In Vitro Diagnostics industry. The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace.

This research study also integrates Industry Chain analysis and Porter’s Five Forces Analysis. Further, this report offers a competitive scenario that comprises collaborations, market concentration rate and expansions, mergers & acquisitions undertaken by companies. The report provides the overall revenue of the global In Vitro Diagnostics Market from 2016 to 2027, considering 2020 as the base year and 2027 as the forecast year.

Market Estimations:

Market Was Valued In 2019 US$ 65.4 Billion
Market Is Projected To Grow By 2027 US$ 85.23 Billion
Compound Annual Growth Rate (CAGR) 5 percent from 2020 to 2027

In vitro diagnostics are medical devices that are diagnoses a medical condition using assays and reagents. Tests can be performed on tissue or blood taken from human body. IVD become essential tool in order to diagnose and identify diseases plus offers projection and forecasting treatment response in clinical practice. Various in vitro diagnostics techniques available at present include hematology, immunodiagnostics, molecular diagnostics and tissue diagnostics. In vitro diagnostic can also be utilized to check a person’s health condition and offer them preventive measures. These IVDs may include next generation tests which require scanning persons DNA to detect genomic variations. Increasing demand for self-tests and point-of-care is projected to accelerate the growth of IVD treatments. Point-of-care testing segment of IVD market is growing rapidly as healthcare systems increasing their reliance on these technologies for informed patient care decisions with easy-to-use tests that offer speed and accuracy.

Development in molecular diagnostics and growing adoption of precision medicine has extended in vitro diagnostics application areas in modern medicine. Additionally, diagnostics center invests enough amounts on Research and Development. For instance, in 2018, players such as Roche, Sysmex and bioMerieuxspent around USD 1.4 billion, USD 158 million and USD 326 million respectively on R&D activities.

Get the Sample Pages of Report for More Understanding@ https://www.precedenceresearch.com/sample/1130

Report Highlights

  • Existence of research organizations that offer clinical research, consulting services, and laboratory testing to cater the swelling demand for rapid diagnosis and treatment plans is likely to fuel the IVD market.
  • The growth of the IVD market is attributed to increasing geriatric population and rapid prevalence of acute and chronic diseases.
  • The in vitro diagnostic may include next generation sequencing tests which diagnoses persons DNA to catch genomic variations.
  • Emerging economies are predicted to offer lucrative opportunities for key players in the IVD market.

Growth Factors

The in vitro diagnostics market is expected to grow at a CAGR of around 5% over the forecast period and the market growth is majorly driven by increasing geriatric population. United Nations forecasted there were around 962 million people with age beyond 60 years in 2017. Further, substantial growth in the prevalence of acute as well as chronic diseases, growing adoption of automatic means and automation in laboratories will drive the IVD market. Growth in the condition specific tests increases significance for IVD tests in developing countries such as India and China which in turn propel the opportunities for key players in the market. Major factors driving the growth are technological advancement as well as focus of key players on constant introduction of innovative products. In addition, availability of Medicaid and Medicare facilities owing to increasing demand for disease diagnosis using IVD is projected to fuel growth in the IVD market over the forecast period. However, rigorous government regulations and adverse reimbursement policy may hinder the IVD market growth. Nonetheless, developing economies offers lucrative growth opportunities for manufacturers involved in the in vitro diagnostics market.

Increasing global spending on healthcare owing to increasing geriatric population and growing adoption of treatments and continuous advancements in technology is expected to propel the in vitro diagnostics market growth in the near future. However, the growth in developed market is predicted to remain steady whereas Asia Pacific and other developing markets will lead the in vitro diagnostics market over the forecast period.

Regional Snapshot

North American led to in vitro diagnostics market in 2019, owing to supportive government regulations, leading healthcare infrastructure and advancements into in vitro diagnostics system. In addition, owing to increasing awareness regarding viral disease detection and development of in vitro diagnostics kits for hospital labs is expected to drive the market growth in North America. For example, Lexent Bio entered partnership with Illuminia, Inc. in order to develop an IVD in vitro diagnostic kit for product offering of next generation sequencing based cancer diagnostics. On the other hand, Asia Pacific is anticipated to witness highest CAGR during the estimated time. Huge target population and upgrading healthcare infrastructure boosts the growth of IVD market in the region.

COVID-19 Impact on In Vitro Diagnostics Market Sales

Businesses today are operating in a dynamic environment. Earlier focus primarily concentrated on keeping pace with changing consumer preferences. COVID-19 outbreak was unprecedented and exposed vulnerabilities of various industries. Pandemic-induces obstacles also were registered in the n Vitro Diagnostics market.

Sales plummeted as COVID-19 gradually tightened its noose worldwide. Supply-chain disruptions caused massive losses, while demand took nose-dive as consumers remained indoors with affected countries implementing either partial or complete lockdown.

Gradual recovery however is on the cards with the roll out of vaccinations. Nonetheless, consecutive waves of the virus compelled businesses to stay prepared for the worst. As government and healthcare organizations successfully implement steps to contain the spread of COVID-19, industries have begun operations, albeit at a slow and more cautious pace.

Against this backdrop, Precedence Research’s study predicts gradual recovery for the n Vitro Diagnostics market 2021 onwards. This trend will however continue through the course of the report’s assessment period

Key Players & Strategies

The in vitro diagnostics market is intensively competitive with presence of a large number of emerging players. The key market players include Alere, Inc., Hoffmann-La Roche Ltd., Arkray, Beckman coulter and many others. Major players in the market are developing innovative products and planning strategic initiatives, like mergers, acquisitions and collaborations in order to acquire significant market share and extend their product range. For instance, in 2018, Roche Diagnostics dominated the industry and revenues were double that of its competitors in the same year. Abbott Diagnostics acquired Alere and firmly held the second position in revenue. This acquisition led Abbott as the leader in point of care testing across the globe.

Market Segmentation

By Product

  • Reagents
  • Instruments
  • Services

By Technology

  • Hematology
  • Reagents
  • Instruments
  • Service
  • Molecular Diagnostics
  • Reagents
  • Instruments
  • Services
  • Immunology
  • Reagents
  • Instruments
  • Services
  • Coagulation
  • Reagents
  • Instruments
  • Services
  • Clinical Chemistry
  • Reagents
  • Instruments
  • Services
  • Microbiology
  • Reagents
  • Instruments
  • Services
  • Others
  • Reagents
  • Instruments
  • Services

 By Application

  • Diabetes
  • Cardiology
  • Nephrology
  • Infectious Disease
  • Oncology
  • Drug Testing
  • Autoimmune Diseases
  • Others

 By Regional

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Middle East & Africa
  • Latin America

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. In Vitro Diagnostics (IVD) Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on In Vitro Diagnostics (IVD) Market

5.1. Covid-19: In Vitro Diagnostics (IVD) Industry Impact
5.2. In Vitro Diagnostics (IVD) Business Impact Assessment: Covid-19
5.2.1. Supply Chain Challenges/Disruption
5.2.2. Market Trends and In Vitro Diagnostics (IVD) Opportunities in the COVID-19 Landscape
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for In Vitro Diagnostics (IVD) Manufacturers to deal with Covid-19 Pandemic Scenario

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition

Chapter 7. Global In Vitro Diagnostics (IVD) Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. In Vitro Diagnostics (IVD) Market Revenue by Manufacturer (2015-2020)
7.1.1.2. In Vitro Diagnostics (IVD) Market Revenue Market Share by Manufacturer (2015-2020)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Capacity Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers

Chapter 8. Global In Vitro Diagnostics (IVD) Market, By Product Type

8.1. In Vitro Diagnostics (IVD) Market, by Product Type, 2016-2027
8.1.1. Reagents
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Instruments
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Services
8.1.3.1. Market Revenue and Forecast (2016-2027)

Chapter 9. Global In Vitro Diagnostics (IVD) Market, By Technology

9.1. In Vitro Diagnostics (IVD) Market, By Technology, 2016-2027
9.1.1. Hematology
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Molecular Diagnostics
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Immunology
9.1.3.1. Market Revenue and Forecast (2016-2027)
9.1.4. Coagulation
9.1.4.1. Market Revenue and Forecast (2016-2027)
9.1.5. Clinical Chemistry
9.1.5.1. Market Revenue and Forecast (2016-2027)
9.1.6. Microbiology
9.1.6.1. Market Revenue and Forecast (2016-2027)
9.1.7. Other
9.1.7.1. Market Revenue and Forecast (2016-2027)

Chapter 10. Global In Vitro Diagnostics (IVD) Market, By Application

10.1. In Vitro Diagnostics (IVD) Market, By Application, 2016-2027
10.1.1. Diabetes
10.1.1.1. Market Revenue and Forecast (2016-2027)
10.1.2. Cardiology
10.1.2.1. Market Revenue and Forecast (2016-2027)
10.1.3. Nephrology
10.1.3.1. Market Revenue and Forecast (2016-2027)
10.1.4. Infectious Disease
10.1.4.1. Market Revenue and Forecast (2016-2027)
10.1.5. Oncology
10.1.5.1. Market Revenue and Forecast (2016-2027)
10.1.6. Drug Testing
10.1.6.1. Market Revenue and Forecast (2016-2027)
10.1.7. Autoimmune Diseases
10.1.7.1. Market Revenue and Forecast (2016-2027)
10.1.8. Others
10.1.8.1. Market Revenue and Forecast (2016-2027)

Chapter 11. Global In Vitro Diagnostics (IVD) Market, Regional Estimates and Trend Forecast

11.1. North America
11.1.1. Market Revenue Forecast by Product (2016-2027)
11.1.2. Market Revenue Forecast By Technology (2016-2027)
11.1.3. Market Revenue Forecast By Application (2016-2027)
11.1.4. Market Revenue Forecast by Technology (2016-2027)
11.1.5. U.S
11.1.5.1. Market Revenue Forecast (2016-2027)
11.1.5.2. Market Revenue Forecast (2016-2027)
11.1.6. Canada
11.1.6.1. Market Revenue Forecast (2016-2027)
11.1.6.2. Market Revenue Forecast (2016-2027)
11.2. Europe
11.2.1. Market Revenue Forecast by Product (2016-2027)
11.2.2. Market Revenue Forecast By Technology (2016-2027)
11.2.3. Market Revenue Forecast By Application (2016-2027)
11.2.4. Market Revenue Forecast by Technology (2016-2027)
11.2.5. UK
11.2.5.1. Market Revenue Forecast (2016-2027)
11.2.5.2. Market Revenue Forecast (2016-2027)
11.2.6. Germany
11.2.6.1. Market Revenue Forecast (2016-2027)
11.2.6.2. Market Revenue Forecast (2016-2027)
11.2.7. France
11.2.7.1. Market Revenue Forecast (2016-2027)
11.2.7.2. Market Revenue Forecast (2016-2027)
11.2.8. Rest of EU
11.2.8.1. Market Revenue Forecast (2016-2027)
11.2.8.2. Market Revenue Forecast (2016-2027)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Product (2016-2027)
11.3.2. Market Revenue Forecast By Technology (2016-2027)
11.3.3. Market Revenue Forecast By Application (2016-2027)
11.3.4. Market Revenue Forecast by Technology (2016-2027)
11.3.5. China
11.3.5.1. Market Revenue Forecast (2016-2027)
11.3.5.2. Market Revenue Forecast (2016-2027)
11.3.6. India
11.3.6.1. Market Revenue Forecast (2016-2027)
11.3.6.2. Market Revenue Forecast (2016-2027)
11.3.7. Japan
11.3.7.1. Market Revenue Forecast (2016-2027)
11.3.7.2. Market Revenue Forecast (2016-2027)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue Forecast (2016-2027)
11.3.8.2. Market Revenue Forecast (2016-2027)
11.4. LATAM
11.4.1. Market Revenue Forecast by Product (2016-2027)
11.4.2. Market Revenue Forecast By Technology (2016-2027)
11.4.3. Market Revenue Forecast By Application (2016-2027)
11.4.4. Market Revenue Forecast by Technology (2016-2027)
11.4.5. Brazil
11.4.5.1. Market Revenue Forecast (2016-2027)
11.4.5.2. Market Revenue Forecast (2016-2027)
11.4.6. Rest of LATAM
11.4.6.1. Market Revenue Forecast (2016-2027)
11.4.6.2. Market Revenue Forecast (2016-2027)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Product (2016-2027)
11.5.2. Market Revenue Forecast By Technology (2016-2027)
11.5.3. Market Revenue Forecast By Application (2016-2027)
11.5.4. Market Revenue Forecast by Technology (2016-2027)
11.5.5. GCC
11.5.5.1. Market Revenue Forecast (2016-2027)
11.5.5.2. Market Revenue Forecast (2016-2027)
11.5.6. North Africa
11.5.6.1. Market Revenue Forecast (2016-2027)
11.5.6.2. Market Revenue Forecast (2016-2027)
11.5.7. South Africa
11.5.7.1. Market Revenue Forecast (2016-2027)
11.5.7.2. Market Revenue Forecast (2016-2027)
11.5.8. Rest of MEA
11.5.8.1. Market Revenue Forecast (2016-2027)
11.5.8.2. Market Revenue Forecast (2016-2027)

Chapter 12. Company Profiles

12.1. Alere, Inc.
12.1.1. Company Overview, Business Information, Manufacturing Area
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Application
12.1.3. Revenue and Gross Margin (2015-2020)
12.1.4. Recent Developments and Strategies
12.2. Hoffmann-La Roche Ltd.
12.2.1. Company Overview, Business Information, Manufacturing Area
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Application
12.2.3. Revenue and Gross Margin (2015-2020)
12.2.4. Recent Developments and Strategies
12.3. Arkray
12.3.1. Company Overview, Business Information, Manufacturing Area
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Application
12.3.3. Revenue and Gross Margin (2015-2020)
12.3.4. Recent Developments and Strategies
12.4. Beckman Coulter
12.4.1. Company Overview, Business Information, Manufacturing Area
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Application
12.4.3. Revenue and Gross Margin (2015-2020)
12.4.4. Recent Developments and Strategies
12.5. Becton Disckinson
12.5.1. Company Overview, Business Information, Manufacturing Area
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Application
12.5.3. Revenue and Gross Margin (2015-2020)
12.5.4. Recent Developments and Strategies
12.6. Bio-Rad laboratories
12.6.1. Company Overview, Business Information, Manufacturing Area
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Application
12.6.3. Revenue and Gross Margin (2015-2020)
12.6.4. Recent Developments and Strategies
12.7. bioMerieux S.A.
12.7.1. Company Overview, Business Information, Manufacturing Area
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Application
12.7.3. Revenue and Gross Margin (2015-2020)
12.7.4. Recent Developments and Strategies
12.8. Danaher
12.8.1. Company Overview, Business Information, Manufacturing Area
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Application
12.8.3. Revenue and Gross Margin (2015-2020)
12.8.4. Recent Developments and Strategies
12.9. Sysmex Corporation
12.9.1. Company Overview, Business Information, Manufacturing Area
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Application
12.9.3. Revenue and Gross Margin (2015-2020)
12.9.4. Recent Developments and Strategies
12.10. Abbott Laboratories
12.10.1. Company Overview, Business Information, Manufacturing Area
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Application
12.10.3. Revenue and Gross Margin (2015-2020)
12.10.4. Recent Developments and Strategies
12.11. Company 11
12.11.1. Company Overview, Business Information, Manufacturing Area
12.11.2. Product Portfolio Analysis
12.11.2.1. Product Details, Specification, Application
12.11.3. Revenue and Gross Margin (2015-2020)
12.11.4. Recent Developments and Strategies
12.12. Company 12
12.12.1. Company Overview, Business Information, Manufacturing Area
12.12.2. Product Portfolio Analysis
12.12.2.1. Product Details, Specification, Application
12.12.3. Revenue and Gross Margin (2015-2020)
12.12.4. Recent Developments and Strategies

Chapter 13. Research Methodology

13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions

Chapter 14. Appendix

14.1. About Us
14.2. Glossary of Terms

Purchase This Premium Research Report @ https://www.precedenceresearch.com/checkout/1130

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semiconductors, chemicals, automotive, and aerospace & defense, among different ventures, present globally.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Bloghttps://precedenceresearchnews.wordpress.com

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

View all posts by Precedence Research →

Leave a Reply

Your email address will not be published. Required fields are marked *